BioXcel Therapeutics (BTAI) Competitors $2.86 +0.32 (+12.56%) As of 03:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI vs. ELYM, GRCE, MURA, HYPD, COEP, ZIVO, PLUR, STTK, MDCX, and CLSDShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Eliem Therapeutics (ELYM), Grace Therapeutics (GRCE), Mural Oncology (MURA), Hyperion DeFi (HYPD), Coeptis Therapeutics (COEP), ZIVO Bioscience (ZIVO), Pluri (PLUR), Shattuck Labs (STTK), Medicus Pharma (MDCX), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. Its Competitors Eliem Therapeutics Grace Therapeutics Mural Oncology Hyperion DeFi Coeptis Therapeutics ZIVO Bioscience Pluri Shattuck Labs Medicus Pharma Clearside Biomedical Eliem Therapeutics (NASDAQ:ELYM) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation. Which has more volatility & risk, ELYM or BTAI? Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Do insiders and institutionals believe in ELYM or BTAI? 69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 21.2% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings & valuation, ELYM or BTAI? Eliem Therapeutics has higher earnings, but lower revenue than BioXcel Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEliem TherapeuticsN/AN/A-$35.12M-$0.53-3.21BioXcel Therapeutics$2.27M7.63-$59.60M-$13.55-0.21 Do analysts recommend ELYM or BTAI? BioXcel Therapeutics has a consensus target price of $42.60, indicating a potential upside of 1,390.03%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Is ELYM or BTAI more profitable? Eliem Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -2,163.18%. BioXcel Therapeutics' return on equity of 0.00% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eliem TherapeuticsN/A -47.03% -45.97% BioXcel Therapeutics -2,163.18%N/A -83.80% Does the media favor ELYM or BTAI? In the previous week, Eliem Therapeutics and Eliem Therapeutics both had 1 articles in the media. Eliem Therapeutics' average media sentiment score of 0.00 equaled BioXcel Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eliem Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioXcel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBioXcel Therapeutics beats Eliem Therapeutics on 9 of the 14 factors compared between the two stocks. Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.50M$3.02B$5.54B$9.44BDividend YieldN/A2.46%4.73%4.14%P/E Ratio-0.2317.7728.9824.27Price / Sales7.63181.87374.6378.80Price / CashN/A40.5624.4827.20Price / Book-0.108.898.635.81Net Income-$59.60M-$54.98M$3.24B$264.73M7 Day Performance79.81%1.90%0.24%-1.14%1 Month Performance45.87%17.13%8.00%5.97%1 Year Performance-80.58%14.73%30.02%23.59% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics3.7139 of 5 stars$2.86+12.6%$42.60+1,390.0%-84.0%$18.50M$2.27M-0.2390Gap DownHigh Trading VolumeELYMEliem TherapeuticsN/A$1.45-2.0%N/A-81.6%$43.14MN/A-2.749GRCEGrace TherapeuticsN/A$3.03-1.6%$12.00+296.0%N/A$42.59MN/A-3.40N/APositive NewsUpcoming EarningsMURAMural Oncology2.7127 of 5 stars$2.41-0.4%$12.00+397.9%-42.9%$41.84MN/A0.00119News CoverageEarnings ReportUpcoming EarningsAnalyst UpgradeHYPDHyperion DeFi0.3559 of 5 stars$9.50+23.4%$2.00-78.9%-92.7%$41.28M$60K-0.1640Upcoming EarningsGap DownCOEPCoeptis TherapeuticsN/A$12.00+3.2%N/A+184.8%$40.87MN/A0.002Positive NewsGap UpZIVOZIVO BioscienceN/A$10.70-3.2%N/A+58.8%$40.84M$15.85K-2.1910Upcoming EarningsGap UpPLURPluri2.09 of 5 stars$5.38+4.3%$12.00+123.0%-5.1%$40.58M$330K0.00150Positive NewsGap UpSTTKShattuck Labs3.1565 of 5 stars$0.82-3.0%$7.50+813.5%-79.7%$40.54M$5.72M-0.59100News CoverageUpcoming EarningsGap UpMDCXMedicus Pharma2.1995 of 5 stars$2.44-16.7%$23.50+863.1%N/A$39.77MN/A-2.10N/ANews CoverageCLSDClearside Biomedical2.4031 of 5 stars$0.45-10.5%$4.20+843.6%-62.6%$38.64M$1.66M-1.0930Upcoming EarningsGap Down Related Companies and Tools Related Companies Eliem Therapeutics Alternatives Grace Therapeutics Alternatives Mural Oncology Alternatives Hyperion DeFi Alternatives Coeptis Therapeutics Alternatives ZIVO Bioscience Alternatives Pluri Alternatives Shattuck Labs Alternatives Medicus Pharma Alternatives Clearside Biomedical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTAI) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BTAI Stock Alerts